These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32171713)

  • 21. Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions.
    Glücklich N; Carle S; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2021 Nov; 166():105980. PubMed ID: 34419573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic understanding of metal-catalyzed oxidation of polysorbate 80 and monoclonal antibody in biotherapeutic formulations.
    Bensaid F; Dagallier C; Authelin JR; Audat H; Filipe V; Narradon C; Guibal P; Clavier S; Wils P
    Int J Pharm; 2022 Mar; 615():121496. PubMed ID: 35074436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.
    Aryal B; Lehtimaki M; Rao VA
    Pharm Res; 2024 Jun; 41(6):1217-1232. PubMed ID: 38740663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detailed profiling of polysorbate 80 oxidative degradation products and hydrolysates using liquid chromatography-tandem mass spectrometry analysis.
    Konya Y; Ochiai R; Fujiwara S; Tsujino K; Okumura T
    Rapid Commun Mass Spectrom; 2024 Apr; 38(7):e9715. PubMed ID: 38351644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
    Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
    Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel markers to track oxidative polysorbate degradation in pharmaceutical formulations.
    Dahotre S; Tomlinson A; Lin B; Yadav S
    J Pharm Biomed Anal; 2018 Aug; 157():201-207. PubMed ID: 29803911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for the Use of Polysorbates in Biopharmaceuticals.
    Jones MT; Mahler HC; Yadav S; Bindra D; Corvari V; Fesinmeyer RM; Gupta K; Harmon AM; Hinds KD; Koulov A; Liu W; Maloney K; Wang J; Yeh PY; Singh SK
    Pharm Res; 2018 May; 35(8):148. PubMed ID: 29797101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
    Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
    J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of long-term polysorbate degradation according to short-term degradation kinetics.
    Zhang S; Riccardi C; Carlson D; Kamen D; Graham KS; Shameem M; Bak H; Xiao H; Li N
    MAbs; 2023; 15(1):2232486. PubMed ID: 37415319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acidic and alkaline hydrolysis of polysorbates under aqueous conditions: Towards understanding polysorbate degradation in biopharmaceutical formulations.
    Dwivedi M; Buske J; Haemmerling F; Blech M; Garidel P
    Eur J Pharm Sci; 2020 Mar; 144():105211. PubMed ID: 31931121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability.
    Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P
    Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of the Water Evaporation Rate and Saccharide Excipients on the Oxidative Degradation of Polysorbates During Oven Drying and Spray Drying.
    Pinto JT; Rajkovaca M; Paudel A
    J Pharm Sci; 2023 Jan; 112(1):36-39. PubMed ID: 36334810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydrolysis of Polysorbate 20 and 80 by a Range of Carboxylester Hydrolases.
    McShan AC; Kei P; Ji JA; Kim DC; Wang YJ
    PDA J Pharm Sci Technol; 2016; 70(4):332-45. PubMed ID: 27020650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-line coupling of hydrophobic interaction column with reverse phase column -charged aerosol detector/mass spectrometer to characterize polysorbates in therapeutic protein formulations.
    He Y; Brown P; Bailey Piatchek MR; Carroll JA; Jones MT
    J Chromatogr A; 2019 Feb; 1586():72-81. PubMed ID: 30551943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring polysorbate 80 degradation in protein solutions using Total Holographic Characterization.
    Markus T; Lumer J; Stasavage R; Ruffner DB; Philips LA; Cheong FC
    Int J Pharm; 2024 Mar; 652():123843. PubMed ID: 38266941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of UPLC-UV-ELSD Method for Fatty Acid Profiling in Polysorbate 80 and Confirmation of the Presence of Conjugated Fatty Acids by Mass Spectrometry, UV Absorbance and Proton Nuclear Magnetic Resonance Spectroscopy.
    Doyle M; Barnes A; Larson NR; Liu H; Yi L
    J Pharm Sci; 2023 Sep; 112(9):2393-2403. PubMed ID: 37295606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.
    Zhang J; He J; Smith KJ
    J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.